Acs Fall 2024 Vvd-130037

Acs Fall 2024 Vvd-130037. Vividion has already disclosed work on covalent keap1 inhibitors, but at the recent acs fall 2024 meeting, the structure and discovery story of their clinical oral covalent activator of. Trial participants will have a histologically confirmed metastatic or unresectable solid tumor.


Acs Fall 2024 Vvd-130037

Explore acs fall 2024 agenda: Technical sessions, networking, career development & more.

Acs Fall 2024 Vvd-130037 Images References :